








WHAT IS CLAIMED IS:

1. A compound selected from:


,

,

, and

,

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 selected from:


,

,

,

, and

, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof,

which is:

((3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-1'*H*,2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl)[8-(methoxymethyl)-6-(trifluoromethyl)imidazo[1,2-*a*]pyridin-2-yl]methanone,


(6-bromo-8-((*S*)-1-methoxyethyl)imidazo[1,2-*a*]pyridin-2-yl)((3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl)methanone,

(6-bromo-8-((*R*)-1-methoxyethyl)imidazo[1,2-*a*]pyridin-2-yl)((3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl)methanone,

(6-bromo-7-methylimidazo[1,2-*a*]pyrimidin-2-yl)[(3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-1'*H*,2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl]methanone, or


(6-cyclopropylimidazo[1,2-*a*]pyrimidin-2-yl)[(3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-1'*H*,2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl]methanone.

4. The compound of claim 1, which is:




, or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1, which is:




, or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1, which is:



, or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1, which is:



, or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1, which is: ((3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-1'*H*,2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl)[8-(methoxymethyl)-6-(trifluoromethyl)imidazo[1,2-*a*]pyridin-2-yl]methanone, or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1, which is: (6-bromo-8-((*S*)-1-methoxyethyl)imidazo[1,2-*a*]pyridin-2-yl)((3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl)methanone, or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1, which is: (6-bromo-8-((*R*)-1-methoxyethyl)imidazo[1,2-*a*]pyridin-2-yl)((3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl)methanone, or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1, which is: (6-bromo-7-methylimidazo[1,2-*a*]pyrimidin-2-yl)[(3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-1'*H*,2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl]methanone, or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1, which is: (6-cyclopropylimidazo[1,2-*a*]pyrimidin-2-yl)[(3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-1'*H*,2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl]methanone, or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition comprising a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, for treating cancer.

~~15. The method for treating cancer comprising administering to a patient in need thereof a compound of any of claims 1-12, or a pharmaceutically acceptable salt thereof.~~

~~16.~~15. The use of ~~method for treating sickle cell disease comprising administering to a patient in need thereof~~ a compound of any of claims 1-12, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating sickle cell disease.

~~17.~~16. The use of ~~method for treating hereditary persistence of foetal hemoglobin (HPFH) mutations comprising administering to a patient in need thereof~~ a compound of any of claims 1-12, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating hereditary persistence of foetal hemoglobin (HPFH) mutations.

~~18.~~17. The use of a compound of any of claims 1-12, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating cancer.